...
首页> 外文期刊>Addiction >Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the 'Treating 3 million by 2005. Making it happen. The WHO strategy' ('3by5')*.
【24h】

Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the 'Treating 3 million by 2005. Making it happen. The WHO strategy' ('3by5')*.

机译:在“到2005年治疗300万人”结束之前的一年,为发展中国家和转型国家的注射吸毒者提供抗逆转录病毒治疗。 WHO策略”(“ 3by5”)*。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To describe and estimate the availability of antiretroviral treatment (ART) to injecting drug users (IDUs) in developing and transitional countries. Literature review of grey and published literature and key informants' communications on the estimated number of current/former injecting drug users (IDUs) receiving ART and the proportion of human immunodeficiency virus (HIV) attributed to injecting drug use (IDU), the number of people in ART and in need of ART, the number of people living with HIV/acquired immunodeficiency syndrome (AIDS) (PLWHA) and the main source of ART. Data on former/current IDUs on ART were available from 50 countries (in 19 countries: nil IDUs in treatment) suggesting that approximately 34 000 IDUs were receiving ART by the end of 2004, of whom 30 000 were in Brazil. In these 50 countries IDUs represent approximately 15% of the people in ART. In Eastern European and Central Asia IDU are associated with > 80% of HIV cases but only approximately 2000 (14%) of the people in ART. In South and South-East Asia there were approximately 1700 former/current IDUs receiving ART ( approximately 1.8% of the people in ART), whereas the proportion of HIV cases associated to IDU is > 20% in five countries (and regionally ranges from 4% to 75%). There is evidence that the coverage of ART among current/former IDUs is proportionally substantially less than other exposure categories. Ongoing monitoring of ART by exposure and population subgroups is critical to ensuring that scale-up is equitable, and that the distribution of ART is, at the very least, transparent.
机译:描述和评估发展中国家和转型国家注射毒品使用者(IDU)的抗逆转录病毒治疗(ART)的可用性。灰色和已发表文献的文献综述以及主要信息提供者的信息,涉及接受ART的当前/前注射吸毒者(IDU)的估计数量以及归因于注射吸毒(IDU)的人类免疫缺陷病毒(HIV)的比例,接受抗逆转录病毒治疗和需要抗逆转录病毒治疗的人,艾滋病毒/后天免疫机能丧失综合症(艾滋病)感染人数和抗逆转录病毒疗法的主要来源。可以从50个国家(在19个国家中,没有接受治疗的注射毒品者)获得关于抗逆转录病毒药物以前/当前注射毒品的数据,这表明到2004年底约有3.4万注射毒品使用者接受抗逆转录病毒治疗,其中3万在巴西。在这50个国家中,注射吸毒者约占抗逆转录病毒治疗人口的15%。在东欧和中亚,注射毒品者与超过80%的艾滋病毒病例有关,但在抗逆转录病毒疗法中仅约2000人(14%)。在南亚和东南亚,约有1700名接受过抗逆转录病毒治疗的前/现任注射毒品者(约占抗病毒治疗人数的1.8%),而在五个国家中,与注射毒品者有关的艾滋病毒病例比例> 20%(区域范围从4个%至75%)。有证据表明,当前/以前的注射毒品使用者中抗病毒治疗的覆盖率比其他暴露类别要小得多。对暴露人群和人群亚组进行持续的ART监测对于确保扩大规模是公平的,并且ART的分布至少是透明的至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号